1
|
Lozano R, Naghavi M, Foreman K, Lim S,
Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et
al: Global and regional mortality from 235 causes of death for 20
age groups in 1990 and 2010: A systematic analysis for the global
burden of disease study 2010. Lancet. 380:2095–2128. 2012.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Miravitlles M, Calle M and Soler-Cataluña
JJ: Clinical phenotypes of COPD: Identification, definition and
implications for guidelines. Arch Bronconeumol. 48:86–98. 2012.In
English, Spanish. View Article : Google Scholar
|
3
|
Vestbo J: COPD: Definition and phenotypes.
Clin Chest Med. 35:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Salvi S: Tobacco smoking and environmental
risk factors for chronic obstructive pulmonary disease. Clin Chest
Med. 35:17–27. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Calverley PM: New treatments for COPD:
Many miles still to go. Lancet Respir Med. 2:6–7. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Tamimi A, Serdarevic D and Hanania NA: The
effects of cigarette smoke on airway inflammation in asthma and
COPD: Therapeutic implications. Respir Med. 106:319–328. 2012.
View Article : Google Scholar
|
7
|
Page CP and Spina D: Selective PDE
inhibitors as novel treatments for respiratory diseases. Curr Opin
Pharmacol. 12:275–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
De Smet EG, Mestdagh P, Vandesompele J,
Brusselle GG and Bracke KR: Non-coding RNAs in the pathogenesis of
COPD. Thorax. 70:782–791. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Li J, Zheng Y, Li MX, Yang CW and Liu YF:
Tanshinone IIA alleviates lipopolysaccharide-induced acute lung
injury by downregulating TRPM7 and pro-inflammatory factors. J Cell
Mol Med. 22:646–654. 2018. View Article : Google Scholar
|
10
|
Li D, Wang J, Sun D, Gong X, Jiang H, Shu
J, Wang Z, Long Z, Chen Y, Zhang Z, et al: Tanshinone IIA sulfonate
protects against cigarette smoke-induced COPD and down-regulation
of CFTR in mice. Sci Rep. 8:3762018. View Article : Google Scholar
|
11
|
Zhou L, Zuo Z and Chow MS: Danshen: An
overview of its chemistry, pharmacology, pharmacokinetics, and
clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Long R, You Y, Li W, Jin N, Huang S, Li T,
Liu K and Wang Z: Sodium tanshinone IIA sulfonate ameliorates
experimental coronary no-reflow phenomenon through down-regulation
of FGL2. Life Sci. 142:8–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Han JY, Fan JY, Horie Y, Miura S, Cui DH,
Ishii H, Hibi T, Tsuneki H and Kimura I: Ameliorating effects of
compounds derived from Salvia miltiorrhiza root extract on
microcirculatory disturbance and target organ injury by ischemia
and reperfusion. Pharmacol Ther. 117:280–295. 2008. View Article : Google Scholar
|
14
|
Xu M, Cao F, Liu L, Zhang B, Wang Y, Dong
H, Cui Y, Dong M, Xu D, Liu Y, et al: Tanshinone IIA-induced
attenuation of lung injury in endotoxemic mice is associated with
reduction of hypoxia-inducible factor 1alpha expression. Am J
Respir Cell Mol Biol. 45:1028–1035. 2011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Cheng J, Chen T, Li P, Wen J, Pang N,
Zhang L and Wang L: Sodium tanshinone IIA sulfonate prevents
lipopolysaccharide-induced inflammation via suppressing nuclear
factor-kappaB signaling pathway in human umbilical vein endothelial
cells. Can J Physiol Pharmacol. 96:26–31. 2018. View Article : Google Scholar
|
16
|
Pascual M, Ibanez F and Guerri C: Exosomes
as mediators of neuron-glia communication in neuroinflammation.
Neural Regen Res. 15:796–801. 2020. View Article : Google Scholar :
|
17
|
Rong S, Wang L, Peng Z, Liao Y, Li D, Yang
X, Nuessler AK, Liu L, Bao W and Yang W: The mechanisms and
treatments for sarcopenia: Could exosomes be a perspective research
strategy in the future? J Cachexia Sarcopenia Muscle. 11:348–365.
2020. View Article : Google Scholar : PubMed/NCBI
|
18
|
Li X, Li C, Zhang L, Wu M, Cao K, Jiang F,
Chen D, Li N and Li W: The significance of exosomes in the
development and treatment of hepatocellular carcinoma. Mol Cancer.
19:12020. View Article : Google Scholar : PubMed/NCBI
|
19
|
Ibrahim A and Marbán E: Exosomes:
Fundamental biology and roles in cardiovascular physiology. Ann Rev
Physiol. 78:67–83. 2016. View Article : Google Scholar
|
20
|
Yao X, Wei W, Wang X, Chenglin L,
Björklund M and Ouyang H: Stem cell derived exosomes: microRNA
therapy for age-related musculoskeletal disorders. Biomaterials.
224:1194922019. View Article : Google Scholar : PubMed/NCBI
|
21
|
Cheng N, Du D, Wang X, Liu D, Xu W, Luo Y
and Lin Y: Recent advances in biosensors for detecting
cancer-derived exosomes. Trends Biotechnol. 37:1236–1254. 2019.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Ruan XF, Li YJ, Ju CW, Shen Y, Lei W, Chen
C, Li Y, Yu H, Liu YT, Kim IM, et al: Exosomes from Suxiao Jiuxin
pill-treated cardiac mesenchymal stem cells decrease H3K27
demethylase UTX expression in mouse cardiomyocytes in vitro. Acta
Pharmacol Sin. 39:579–586. 2018. View Article : Google Scholar : PubMed/NCBI
|
23
|
Ruan XF, Ju CW, Shen Y, Liu YT, Kim IM, Yu
H, Weintraub N, Wang XL and Tang Y: Suxiao Jiuxin pill promotes
exosome secretion from mouse cardiac mesenchymal stem cells in
vitro. Acta Pharmacol Sin. 39:569–578. 2018. View Article : Google Scholar : PubMed/NCBI
|
24
|
Maremanda KP, Sundar IK and Rahman I:
Protective role of mesenchymal stem cells and mesenchymal stem
cell-derived exosomes in cigarette smoke-induced mitochondrial
dysfunction in mice. Toxicol Appl Pharmacol. 385:1147882019.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expressiion data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
26
|
Niu XL, Ichimori K, Yang X, Hirota Y,
Hoshiai K, Li M and Nakazawa H: Tanshinone II-A inhibits low
density lipoprotein oxidation in vitro. Free Radic Res. 33:305–312.
2000. View Article : Google Scholar : PubMed/NCBI
|
27
|
Tang F, Wu X, Wang T, Wang P, Li R, Zhang
H, Gao J, Chen S, Bao L, Huang H and Liu P: Tanshinone II A
attenuates atherosclerotic calcification in rat model by inhibition
of oxidative stress. Vascul Pharmacol. 46:427–438. 2007. View Article : Google Scholar : PubMed/NCBI
|
28
|
Yin X, Yin Y, Cao FL, Chen YF, Peng Y, Hou
WG, Sun SK and Luo ZJ: Tanshinone IIA attenuates the inflammatory
response and apoptosis after traumatic injury of the spinal cord in
adult rats. PLoS One. 7:e383812012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Barnes PJ: Development of new drugs for
COPD. Curr Med Chem. 20:1531–1540. 2013. View Article : Google Scholar
|
30
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
32
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
33
|
Hu H, Zhu X and Lin X: GuaLou GuiZhi
decoction represses LPS-induced BV2 activation via miR-155 induced
inflammatory signals. Pak J Pharm Sci. 33:403–408. 2020.PubMed/NCBI
|
34
|
Lin F, Chen HW, Zhao GA, Li Y, He XH,
Liang WQ, Shi ZL, Sun SY, Tian PP, Huang MY and Liu C: Advances in
research on the circRNA-miRNA-mRNA network in coronary heart
disease treated with traditional Chinese medicine. Evid Based
Complement Alternat Med. 17:80486912020.
|
35
|
Tang C, Zhao R, Ni H, Zhao K, He Y, Fang S
and Chen Q: Molecule mechanisms of Ganoderma lucidum treated
hepatocellular carcinoma based on the transcriptional profiles and
miRNA-target network. Biomed Pharmacother. 125:1100282020.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Wang X, Chi J, Dong B, Xu L, Zhou Y, Huang
Y, Sun S, Wei F, Liu Y, Liu C, et al: miR-223-3p and miR-22-3p
inhibit monosodium urate-induced gouty inflammation by targeting
NLRP3. Int J Rheum Dis. 24:599–607. 2021. View Article : Google Scholar : PubMed/NCBI
|
37
|
Hu Z, Lv X, Chen L, Gu X, Qian H,
Fransisca S, Zhang Z, Liu Q and Xie P: Protective effects of
microRNA-22-3p against retinal pigment epithelial inflammatory
damage by targeting NLRP3 inflammasome. J Cell Physiol.
234:18849–18857. 2019. View Article : Google Scholar : PubMed/NCBI
|
38
|
Chai X, Si H, Song J, Chong Y, Wang J and
Zhao G: miR-486-5p inhibits inflammatory response, matrix
degradation and apoptosis of nucleus pulposus cells through
directly targeting FOXO1 in inter-vertebral disc degeneration. Cell
Physiol Biochem. 52:109–118. 2019. View Article : Google Scholar
|
39
|
Yamada K, Takizawa S, Ohgaku Y, Asami T,
Furuya K, Yamamoto K, Takahashi F, Hamajima C, Inaba C, Endo K, et
al: MicroRNA 16-5p is upregulated in calorie-restricted mice and
modulates inflammatory cytokines of macrophages. Gene.
725:1441912020. View Article : Google Scholar
|
40
|
Ruan C, Cong RJ, Wang M, Wang L, Yu Y, Li
X and Lv H: miR-27b-3p targeting BDNF inhibits TrkB/CREB signaling
pathway and improves IL-1 β induced chondrocytic inflammation.
Preprints: 2021020602. 2021.10.20944/preprints202102.0602.v1.
|
41
|
Tian F, Wang J, Ouyang T, Lu N, Lu J, Shen
Y, Bai Y, Xie X and Ge Q: miR-486-5p serves as a good biomarker in
nonsmall cell lung cancer and suppresses cell growth with the
involvement of a target PIK3R1. Front Genet. 10:6882019. View Article : Google Scholar : PubMed/NCBI
|
42
|
Yang S, Sui J, Liu T, Wu W, Xu S, Yin L,
Pu Y, Zhang X, Zhang Y, Shen B and Liang G: Expression of
miR-486-5p and its significance in lung squamous cell carcinoma. J
Cell Biochem. 120:13912–13923. 2019. View Article : Google Scholar : PubMed/NCBI
|
43
|
Zhang Y, Fu J, Zhang Z and Qin H:
miR-486-5p regulates the migration and invasion of colorectal
cancer cells through targeting PIK3R1. Oncol Lett. 15:7243–7248.
2018.PubMed/NCBI
|
44
|
Huang XP, Hou J, Shen XY, Huang CY, Zhang
XH, Xie YA and Luo XL: MicroRNA-486-5p which is downregulated in
hepatocellular carcinoma, suppresses tumor growth by targeting
PIK3R1. FEBS J. 282:579–594. 2015. View Article : Google Scholar
|
45
|
Mirza-Aghazadeh-Attari M, Ekrami EM,
Aghdas SAM, Mihanfar A, Hallaj S, Yousefi B, Safa A and Majidinia
M: Targeting PI3K/Akt/mTOR signaling pathway by polyphenols:
Implication for cancer therapy. Life Sci. 255:1174812020.
View Article : Google Scholar : PubMed/NCBI
|
46
|
Sun K, Luo J, Guo J, Yao X, Jing X and Guo
F: The PI3K/AKT/mTOR signaling pathway in osteoarthritis: A
narrative review. Osteoarthritis Cartilage. 28:400–409. 2020.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Pirozzi F, Ren K, Murabito A and Ghigo A:
PI3K signaling in chronic obstructive pulmonary disease:
Mechanisms, targets, and therapy. Curr Med Chem. 26:2791–2800.
2019. View Article : Google Scholar
|
48
|
Marwick JA, Chung KF and Adcock IM:
Phosphatidylinositol 3-kinase isoforms as targets in respiratory
disease. Ther Adv Respir Dis. 4:19–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
49
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: an open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|